INNV vs. VCYT, ADUS, PACS, ARDT, LFST, PGNY, GRAL, NHC, TDOC, and VRDN
Should you be buying InnovAge stock or one of its competitors? The main competitors of InnovAge include Veracyte (VCYT), Addus HomeCare (ADUS), PACS Group (PACS), Ardent Health (ARDT), LifeStance Health Group (LFST), Progyny (PGNY), GRAIL (GRAL), National HealthCare (NHC), Teladoc Health (TDOC), and Viridian Therapeutics (VRDN). These companies are all part of the "healthcare" industry.
InnovAge vs. Its Competitors
InnovAge (NASDAQ:INNV) and Veracyte (NASDAQ:VCYT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.
InnovAge currently has a consensus target price of $5.00, suggesting a potential upside of 18.06%. Veracyte has a consensus target price of $40.90, suggesting a potential upside of 68.85%. Given Veracyte's stronger consensus rating and higher probable upside, analysts clearly believe Veracyte is more favorable than InnovAge.
In the previous week, Veracyte had 3 more articles in the media than InnovAge. MarketBeat recorded 5 mentions for Veracyte and 2 mentions for InnovAge. InnovAge's average media sentiment score of 0.93 beat Veracyte's score of 0.85 indicating that InnovAge is being referred to more favorably in the media.
Veracyte has lower revenue, but higher earnings than InnovAge. InnovAge is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.
Veracyte has a net margin of 7.13% compared to InnovAge's net margin of -3.75%. Veracyte's return on equity of 6.14% beat InnovAge's return on equity.
12.3% of InnovAge shares are owned by institutional investors. 1.4% of InnovAge shares are owned by company insiders. Comparatively, 1.4% of Veracyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
InnovAge has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, Veracyte has a beta of 2.07, meaning that its share price is 107% more volatile than the S&P 500.
Summary
Veracyte beats InnovAge on 12 of the 15 factors compared between the two stocks.
Get InnovAge News Delivered to You Automatically
Sign up to receive the latest news and ratings for INNV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding INNV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
InnovAge Competitors List
Related Companies and Tools
This page (NASDAQ:INNV) was last updated on 7/17/2025 by MarketBeat.com Staff
Free INNV Stock Alerts